Integrum is granted patent approval for its OPRA™ Implant System in Australia
Mölndal, Sweden, April 27th, 2023 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company has received a patent approval in Australia describing components and design features of the OPRA™ Implant System. The patent period extends until 2037.
Integrum develops the OPRA™ Implant System, a revolutionary implant technology based on the company's deep expertise and innovations in osseointegration, that help amputees regain normal mobility and quality of life.
The current patent includes claims covering the entire system, including the anchoring solution for attaching a prosthesis to the human body as well as the abutment and the abutment screw. These claims extend beyond transfemoral applications, which currently make up most treatment cases, to include treatment in other types of long bone prosthetic applications, such as the upper arm or lower leg.
Further, the claims cover design features for the connection between the abutment and the fixture, allowing a pathway for the communication of physical and biophysical signals between the inside and outside of the human body. Such design aspects are of vital importance to, for example, the e-OPRA™ Implant System - Integrum's state-of-the-art mind-controlled robotic prosthesis.
The patent grants Integrum exclusivity to OPRA™ Implant System from November 7th, 2017, until 2037 and is vital to the company’s commercial success in the Australian market.
"We are very happy to have expanded our reach to Australia with our innovative state-of-the-art products within osseointegration. The next step will be to further implement OPRA™ Implant System as the new standard of care in amputation treatment, and the long-lasting and broad protection the new patent offers will be a key factor in that process,” comments Rickard Brånemark, CEO of Integrum.
